Dr Takayuki Yoshino speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the results from the VOLTAGE trial which investigated nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy in patients with microsatellite stable locally advanced resectable rectal cancer.
He describes the design of this single-arm, phase II study, in which nivolumab was administered every two weeks following chemoradiotherapy.
Dr Yoshino explains the results achieved from this trial, in which a major pathologic complete response rate (pCR) of 38 percent was seen. He also believes that PDL-1 and CD8 expression may be an effective indicator of nivolumab treatment.
He concludes by mentioning that the next step will be to carry out a global trial.